Roche beefs up diagnostics with $100M BioImagene; Aspen posts 25 percent earnings hike;

@FiercePharma: Genzyme shareholder sues to stop Sanofi acquisition. Article | Follow @FiercePharma

> Roche has added to its portfolio of diagnostics products by acquiring U.S.-based BioImagene, which specializes in tissue-based cancer diagnostics, for $100 million. Article

> Africa's biggest generic drugmaker Aspen Pharmacare said full-year headline earnings per share likely rose by 25 percent boosted by its South African operations. Report

> Irish drug maker Warner Chilcott has completed a loan and a debt offering necessary to pay a special dividend of $8.50 per share that it announced last month. Story

> Sun Pharmaceutical Industries said it is planning to enter the Japanese generics market, with drugs aimed at treating chronic diseases. Story

> Novartis is seeking to use Swiss merger law to push through its buy of a minority stake in U.S. eyecare firm Alcon (ACL.N), which would give it full control of the group. Item

> British drugmaker AstraZeneca spent $740,000 in the second quarter lobbying the U.S. federal government, according to a recent disclosure form. News

> GlaxoSmithKline spent just over $1.2 million lobbying federal officials on patent laws and other issues during the second quarter, according to a recent disclosure form. Article

 @FierceBiotech:  Which biotechs are the least efficient? News | Follow @FierceBiotech

Biotech News

> Taligen gets $10M cash injection for rare disease platform. Item

> Hep E vaccine aces large late-stage study in China. Article

> U.S. biotech faces fierce international competition. Story

> EpiCept shares hammered after FDA rejects app, demands new trial. News

> Archimedes starts recruiting for new U.S. headquarters. Report

Biotech IT News

> Roche writes social media rules for employees. Item

> Top 10 list rejects cloud for clinical data. News

> UK study supports dose-response modeling. Story

> Google-like code aids drug development. Report

> NIH funds software-based brain plasticity trials. Article

> Cloud to host Saffron predictive analytics tool. News

And Finally... What happens to attention, memory and learning when we step away from our devices and rest our brains? Report